Fulcrum Therapeutics, Inc.FULC
Price (close)
$3.79
Market cap
$288.7M
P/E
—
Revenue (TTM)
$0
Net income
-$85.0M
Dividend yield
—
1-year total return
-55.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Fulcrum Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $19.2M | $6.3M | $2.8M | $80.0M | $0 |
| Net income | -$70.8M | -$80.8M | -$109.9M | -$97.3M | -$9.7M | -$74.9M |
| Free cash flow | -$55.0M | -$80.2M | -$99.0M | -$91.5M | -$2.5M | -$60.4M |
More on FULC.
- Fulcrum Therapeutics, Inc. summary
- Fulcrum Therapeutics, Inc. financial statements
- Fulcrum Therapeutics, Inc. key metrics
- Fulcrum Therapeutics, Inc. health scores and style box
- Fulcrum Therapeutics, Inc. earnings
- Fulcrum Therapeutics, Inc. dividends
- Fulcrum Therapeutics, Inc. valuation
- Fulcrum Therapeutics, Inc. ownership and insiders
- Fulcrum Therapeutics, Inc. peers
Figures from Fulcrum Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.